PURPOSE: To examine if N-acetylcysteine (NAC) reduces the incidence of contrast nephropathy during endovascular abdominal aortic aneurysm repair (EVAR) as evidenced by changes in markers of renal function. METHODS:Twenty consecutive men (mean age 72 years, range 65-79) undergoing EVAR were randomized to receive standard intravenous fluid hydration or standard fluid hydration and NAC (600 mg BID orally, 4 doses). Venous blood and urine were collected prior to the procedure and for 5 postoperative days and analyzed blindly for serum creatinine, urinary retinol-binding protein (RBP), and albumin/creatinine ratio (ACR). RESULTS: There were no significant differences in baseline demographics between the groups. No patient developed acute renal failure. In both groups, urinary RBP rose significantly from baseline (median 15 microg/mmol to peak 699 microg/mmol in controls versus 17 to 648 microg/mmol in the treatment group, p<0.003). There were similar significant rises in ACR (p<0.02). There was, however, no significant difference in the postoperative RBP or ACR between the groups at any time point. CONCLUSION:EVAR causes significant acute renal injury in most patients. This was not attenuated by N-acetylcysteine. The causes of renal injury are probably multifactorial, the long-term clinical significance of which is unclear.
RCT Entities:
PURPOSE: To examine if N-acetylcysteine (NAC) reduces the incidence of contrast nephropathy during endovascular abdominal aortic aneurysm repair (EVAR) as evidenced by changes in markers of renal function. METHODS: Twenty consecutive men (mean age 72 years, range 65-79) undergoing EVAR were randomized to receive standard intravenous fluid hydration or standard fluid hydration and NAC (600 mg BID orally, 4 doses). Venous blood and urine were collected prior to the procedure and for 5 postoperative days and analyzed blindly for serum creatinine, urinary retinol-binding protein (RBP), and albumin/creatinine ratio (ACR). RESULTS: There were no significant differences in baseline demographics between the groups. No patient developed acute renal failure. In both groups, urinary RBP rose significantly from baseline (median 15 microg/mmol to peak 699 microg/mmol in controls versus 17 to 648 microg/mmol in the treatment group, p<0.003). There were similar significant rises in ACR (p<0.02). There was, however, no significant difference in the postoperative RBP or ACR between the groups at any time point. CONCLUSION: EVAR causes significant acute renal injury in most patients. This was not attenuated by N-acetylcysteine. The causes of renal injury are probably multifactorial, the long-term clinical significance of which is unclear.
Authors: Athanasios Saratzis; Michael F Bath; Seamus Harrison; Robert D Sayers; Asif Mahmood; Pantelis Sarafidis; Matthew J Bown Journal: Clin J Am Soc Nephrol Date: 2015-10-20 Impact factor: 8.237
Authors: Alan Karthikesalingam; Sandeep S Bahia; Shaneel R Patel; Bilal Azhar; Dan Jackson; Lynne Cresswell; Robert J Hinchliffe; Peter J E Holt; Matt M Thompson Journal: Kidney Int Date: 2014-08-20 Impact factor: 10.612
Authors: Pantelis Sarafidis; Sven Martens; Athanasios Saratzis; Daniella Kadian-Dodov; Patrick T Murray; Catherine M Shanahan; Allen D Hamdan; Daniel T Engelman; Ulf Teichgräber; Charles A Herzog; Michael Cheung; Michel Jadoul; Wolfgang C Winkelmayer; Holger Reinecke; Kirsten Johansen Journal: Cardiovasc Res Date: 2022-09-20 Impact factor: 13.081
Authors: Véronique Brulotte; François A Leblond; Stéphane Elkouri; Eric Thérasse; Vincent Pichette; Pierre Beaulieu Journal: Anesthesiol Res Pract Date: 2013-06-12